Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Thousands Of New Mexicans Could Lose Private Insurance, Study Shows
An estimated 428,000 residents in New Mexico could lose their private, employer-based coverage if Congress passes a House health reform bill, according to state-specific analysis of The American Affordable Health Choices Act of 2009 released this week by The Heritage Foundation.

Scripps Discovers Genetic Clues Into Formation Of Cancer Tumors
A new research study from Scripps Health provides previously unknown genetic clues into how cancerous tumors are formed in the human breast, brain and colorectal system. The findings by researchers at Scripps Translational Science Institute (STSI) will be published in the September 2009 edition of the journal Genome Research.
News of the day
Treating Gum Disease Helps Rheumatoid Arthritis Sufferers
Not yet convinced about keeping your healthy teeth, here"s another reason.
Oncology

AVI BioPharma, Inc. To Present At 7th Annual Biodefense Vaccines & Therapeutics Conference In Washington, D.C.

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced that Patrick Iversen, Ph.D., Senior Vice President of Strategic Alliances, will present at the upcoming 7th Annual Biodefense Vaccines & Therapeutics conference taking place in Washington, D.C. Dr. Iversen will present on Monday, June 15, as part of a pre-conference symposium on "Developments in Biodefense Technology Platform." He will be a featured speaker in a session titled "Building Technology Platforms to Array Against Multiple Threats," where he will discuss the utility of AVI"s RNA-based drugs against biological threats, including Ebola and Marburg viruses. AVI has begun to evaluate the rapid mobilization of RNA-based drugs against positive and negative strand RNA viruses. This analysis includes target optimization, avoidance of drug resistance and the relative advantages of virus-specific and host immune response-specific therapeutics to both improve host protection and reduce disease. Information about the conference can be found here. AVI BioPharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009